RAFEN

Main information

  • Trade name:
  • RAFEN IBUPROFEN tablets BP 200mg blister pack
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • RAFEN IBUPROFEN tablets BP 200mg blister pack
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 217313
  • Last update:
  • 09-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

217313

RAFEN IBUPROFEN tablets BP 200mg blister pack

ARTG entry for

Medicine Registered

Sponsor

Alphapharm Pty Ltd

Postal Address

PO Box R1462,ROYAL EXCHANGE, NSW, 1225

Australia

ARTG Start Date

14/11/2013

Product category

Medicine

Status

Active

Approval area

Non-Prescription Medicines

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods

Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered

or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. RAFEN IBUPROFEN tablets BP 200mg blister pack

Product Type

Single Medicine Product

Effective date

14/11/2013

Warnings

No Warnings included on Record

Standard Indications

Specific Indications

Temporary relief of pain and inflammation associated with headache, period pain, dental pain, migraine headache, tension headache, back pain, arthritic

pain, and cold and flu symptoms. Also reduces fever.

Additional Product information

Container information

Type

Material

Life Time

Temperature

Closure

Conditions

Blister Pack

PVC/Al

2 Years

Store below 30

degrees Celsius

Not recorded

Not recorded

Pack Size/Poison information

Pack Size

Poison Schedule

30 Tablets

(S2) Pharmacy Medicine

50 Tablets

(S2) Pharmacy Medicine

Components

1.

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification

White, Circular, Biconvex shaped, film coated tablet with IBU 200

embossed on one side and plain on the other side

Active Ingredients

Ibuprofen

200 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 26.11.2017 at 06:24:10 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

27-7-2018

Pending EC decision:  Tafinlar, dabrafenib, Opinion date: 26-Jul-2018

Pending EC decision: Tafinlar, dabrafenib, Opinion date: 26-Jul-2018

Europe - EMA - European Medicines Agency

27-7-2018

Pending EC decision:  Braftovi, encorafenib, Opinion date: 26-Jul-2018

Pending EC decision: Braftovi, encorafenib, Opinion date: 26-Jul-2018

Europe - EMA - European Medicines Agency

6-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Encorafenib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Encorafenib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

4-5-2018

FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer

FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer

FDA approves Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer

FDA - U.S. Food and Drug Administration

21-2-2017

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls a batch of Pamol® in packs of 300 film-coated tablets after the discovery of Ibumetin 600 mg containing ibuprofen in some packs. Both types of medicine are used for the treatment of mild pain, but they work in different ways and may cause different adverse reactions.

Danish Medicines Agency

24-9-2018

Braftovi (Pierre Fabre MEdicament)

Braftovi (Pierre Fabre MEdicament)

Braftovi (Active substance: encorafenib) - Centralised - Authorisation - Commission Decision (2018)6216 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/004580/0000

Europe -DG Health and Food Safety

24-5-2018

Stivarga (Bayer AG)

Stivarga (Bayer AG)

Stivarga (Active substance: regorafenib) - Centralised - Renewal - Commission Decision (2018)3266 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2573/R/25

Europe -DG Health and Food Safety

24-5-2018

Pedea (Orphan Europe S.A.R.L.)

Pedea (Orphan Europe S.A.R.L.)

Pedea (Active substance: Ibuprofen) - PSUSA - Modification - Commission Decision (2018)3257 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/1712/201707

Europe -DG Health and Food Safety

15-5-2018

Tafinlar (Novartis Europharm Limited)

Tafinlar (Novartis Europharm Limited)

Tafinlar (Active substance: DABRAFENIB) - Centralised - Renewal - Commission Decision (2018)3010 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2604/R/30

Europe -DG Health and Food Safety